Predictive value of FDG-PET in patients with advanced medullary thyroid cancer undergoing vandetanib treatment

被引：0
|
作者：
Werner, Rudolf [2 ,6 ]
Higuchi, Takahiro [4 ]
Muegge, Dirk [4 ]
Javadi, Mehrbod [3 ]
Fassnacht, Martin [5 ]
Buck, Andreas [4 ]
Lapa, Constantin [4 ]
Kreissl, Michael [1 ]
机构：
[1] Hosp Augsburg, Dept Nucl Med, Augsburg, Germany
[2] Johns Hopkins Med Inst, Russell H Morgan Dept Radiol & Radiol Sci, Div Nucl Med, 600 N Wolfe St, Baltimore, MD 21205 USA
[3] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA
[4] Univ Hosp Wuerzburg, Dept Nucl Med, Wurzburg, Germany
[5] Univ Hosp WArzburg, Div Endocrinol & Diabet, Dept Internal Med 1, Wurzburg, Germany
[6] Univ Hosp WArzburg, Else KrAner Forschungskolleg, Dept Nucl Med, Wurzburg, Germany
来源：
JOURNAL OF NUCLEAR MEDICINE | 2017年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
169
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
    Robinson, Bruce G.
    Paz-Ares, Luis
    Krebs, Annetta
    Vasselli, James
    Haddad, Robert
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (06): : 2664 - 2671
  • [32] Retrospective analysis of the safety and efficacy of vandetanib as systemic treatment for patients with advanced and progressive medullary thyroid cancer (MTC)
    Capdevila, Jaume
    Martinez-Trufero, Javier
    Dalmau, Elsa
    Alvarez-Escala, Cristina
    Beltran, Miguel
    Duran, Manuel
    Gallegos, Isabel
    Luis Manzano, Jose
    Mesla, Ricard
    Pajares, Isabel
    Fuentes Pradera, Jose
    Grau, Juan J.
    Reig, Oscar
    Manuel Trigo, Jose
    Grande, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Predictive value of FDG-PET in memory dominance and their correlation
    Hong, SB
    Roh, SY
    Kim, SE
    Seo, DW
    Lee, IK
    Na, DL
    NEUROLOGY, 1996, 46 (02) : 4068 - 4068
  • [34] Critical considerations on the predictive value of end-of-treatment FDG-PET in lymphoma
    Adams, Hugo J. A.
    Kwee, Thomas C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (02) : 342 - 343
  • [35] The Value of 18F FDG PET in Patients with Residual or Recurrent Medullary Thyroid Cancer.
    Bogsrud, T. V.
    Karantanis, D.
    Nathan, M. A.
    Mullan, B. P.
    Wiseman, G. A.
    Collins, D. A.
    Kasperbauer, J. L.
    Strome, S. E.
    Reading, C. C.
    Hay, I. D.
    Lowe, V. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S54 - S54
  • [36] Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma
    Durante, Cosimo
    Paciaroni, Alessandra
    Plasmati, Katia
    Trulli, Fabiana
    Filetti, Sebastiano
    ENDOCRINE, 2013, 44 (02) : 334 - 342
  • [37] Critical considerations on the predictive value of end-of-treatment FDG-PET in lymphoma
    Hugo J. A. Adams
    Thomas C. Kwee
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 342 - 343
  • [38] The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer
    Fallahi, Poupak
    Ferrari, Silvia Martina
    Baldini, Enke
    Biricotti, Marco
    Ulisse, Salvatore
    Materazzi, Gabriele
    Miccoli, Paolo
    Antonelli, Alessandro
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (11) : 1109 - 1118
  • [39] Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
    Deshpande, Hari
    Roman, Sanziana
    Thumar, Jaykumar
    Sosa, Julie Ann
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2011, 5 : 213 - 221
  • [40] Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma
    Cosimo Durante
    Alessandra Paciaroni
    Katia Plasmati
    Fabiana Trulli
    Sebastiano Filetti
    Endocrine, 2013, 44 : 334 - 342
12345